Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sumatriptan succinate Clear all
Completed Phase 3 Interventional Results available

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881
View directory record Official record
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

NCT00329355
View directory record Official record
Conditions
Migraine, Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
35
States / cities
Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
View directory record Official record
Conditions
Delayed Alcohol Induced Headache
Interventions
VVD-101, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Mountain View, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Fresno, California • Newport Beach, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

NCT00510419
View directory record Official record
Conditions
Migraine
Interventions
"Investigational"Auto-injector (sumatriptan succinate)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
San Francisco, California • Stamford, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

NCT00573170
View directory record Official record
Conditions
Migraine Disorders, Migraine, Acute
Interventions
TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2010 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

NCT00648466
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

NCT00846885
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate, Imitrex®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

NCT03229798
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan Succinate Oral Tablet, Transdermal delivery of sumatriptan succinate
Drug · Combination Product
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

NCT02571049
View directory record Official record
Conditions
Rapidly Escalating Migraine
Interventions
DFN-11
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

NCT00875784
View directory record Official record
Conditions
Migraine Disorders
Interventions
TREXIMA™, IMITREX® (4mg), IMITREX® (6mg), IMITREX Tablet 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

NCT00614029
View directory record Official record
Conditions
Pharmacokinetics, Bioequivalence
Interventions
Sumatriptan (via Intraject System)
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

NCT01381796
View directory record Official record
Conditions
Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions
NP101, sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Francisco, California • Kalamazoo, Michigan • Springfield, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Treximet in Acute Migraine Headache: Assessing Cognitive Function

NCT00837044
View directory record Official record
Conditions
Migraine Headache, Cognitive Impairment
Interventions
Treximet, Migraine rescue medication of choice
Drug
Lead sponsor
Neurological Research Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

NCT00546650
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

NCT00650247
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study of NXN 188 for the Treatment of Migraine With Aura

NCT00920686
View directory record Official record
Conditions
Migraine With Aura
Interventions
NXN-188, placebo, sumatriptan succinate
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Newport Beach, California • Oceanside, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

NCT00488514
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993
View directory record Official record
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 19, 2026, 10:15 AM EDT